08/04/2025 - 7:00am Press Releases Ypsomed Group
Burgdorf - Ypsomed Holding AG (SIX: YPSN) announced today that it has successfully completed the sale of its Ypsomed Diabetes Care business to TecMed AG.
The sale of the diabetes care business, initially announced on April 22, 2025, has now been completed. This is a strategic milestone for Ypsomed as it refocuses on its market-leading position in subcutaneous self-injection solutions for pharmaceutical and biotech companies.
The company also confirms the usual transitional service agreements and certain contract manufacturing services will remain in effect following the transaction closing, ensuring continuity of services and a smooth transition.
Media release as PDF
- Ypsomed Completes the Sale of Ypsomed Diabetes Care.pdf (77.7 KiB)
Sam Ghezelbash
Head of M&A & IR
Ypsomed Holding AG
Brunnmattstrasse 6
3401 Burgdorf
Switzerland
3401 Burgdorf
Switzerland
sam.ghezelbash@ypsomed.com
+41 76 228 51 45